Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APLM Stock Forecast 2026-2027
$14.21
Current Price
$31.21M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to APLM Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
APLM Price Momentum
-24.9%
1 Week Change
-0.7%
1 Month Change
+147.6%
1 Year Change
-24.0%
Year-to-Date Change
-66.3%
From 52W High of $42.12
+288.4%
From 52W Low of $3.66
📊 TOP ANALYST CALLS
Did APLM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Apollomics is one of their latest high-conviction picks.
Latest APLM Stock Price Targets & Analyst Predictions
APLM has shown a year-to-date change of -24.0% and a 1-year change of 147.6%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for APLM. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APLM Analyst Ratings
0
Buy
0
Hold
0
Sell
APLM Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $14.21
Latest APLM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APLM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $2.00 |
| Apr 1, 2024 | EF Hutton | Buy | Maintains | $N/A | |
| Apr 1, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 20, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 3, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 23, 2023 | EF Hutton | Michael King | Buy | Assumes | $25.00 |
| Jun 5, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 1, 2023 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| May 25, 2023 | EF Hutton | Michael King | Buy | Assumes | $25.00 |
| Apr 25, 2023 | EF Hutton | Buy | Initiates | $N/A |
Apolomics Inc. (APLM) Competitors
The following stocks are similar to Apollomics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Apolomics Inc. (APLM) Financial Data
Valuation Metrics
Market Cap
$31.21M
Enterprise Value
$38.98M
P/E Ratio
N/A
PEG Ratio
-29.2x
Price/Sales
4.7x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
+431.9%
Net Margin
-123.7%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+10.5%
Current Ratio
1.0x
Debt/Equity
-0.2x
ROE
-1,305.4%
ROA
-57.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Apolomics Inc. (APLM) Business Model
About Apolomics Inc.
What They Do
Develops innovative oncology therapies targeting cancer.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, focusing on the discovery and development of therapies that harness the immune system to combat cancer. It generates revenue through the advancement of its clinical assets, including late-stage candidates, which may lead to partnerships, licensing agreements, or eventual product sales upon successful commercialization.
Additional Information
Apolomics Inc. was founded in 2015 and is headquartered in Foster City, California, with operations in Taipei, Taiwan. The company aims to address significant unmet medical needs in challenging cancer types and has a diverse pipeline that includes candidates in various phases of clinical trials, showcasing its commitment to innovative oncology solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Mr. Hung-Wen Chen
Country
United States
IPO Year
2021
Website
www.apollomicsinc.comApolomics Inc. (APLM) Latest News & Analysis
Latest News
Quick Summary
Apollomics Inc. (Nasdaq: APLM) has received a notice from Nasdaq regarding non-compliance with the $35 million minimum Market Value of Listed Securities requirement for continued listing.
Why It Matters
Apollomics Inc.'s non-compliance with Nasdaq's minimum market value requirement raises concerns about its financial health and potential delisting, impacting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
2 months ago
Quick Summary
Phase 2 studies of vebreltinib, a potent c-MET inhibitor, are ongoing, with over 600 patients and 170 healthy volunteers dosed, indicating progress in its global development.
Why It Matters
Positive Phase 2 results for vebreltinib could lead to significant advancements in treatment options, potentially boosting the company’s market position and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Apollomics Inc. (Nasdaq: APLM) has secured a $2.0 million unsecured Convertible Promissory Note, as announced on April 1, 2026.
Why It Matters
Apollomics securing a $2.0 million convertible note may indicate financial support for growth or development, potentially impacting stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Apollomics Reports First Half 2025 Financial Results
6 months ago
Quick Summary
Apollomics Inc. (Nasdaq: APLM) reported its financial results for H1 2025, focusing on its late-stage oncology drug candidates aimed at challenging cancers.
Why It Matters
Apollomics' financial results indicate its progress in developing oncology drugs, impacting its market position and potential for future growth, directly influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Apollomics Announces Settlement of Cayman Litigation
7 months ago
Quick Summary
Apollomics Inc. (Nasdaq: APLM) has reached a settlement with TWVC Goldlink Partners and TWVC Panglin Group regarding ongoing litigation in the Cayman Islands.
Why It Matters
The settlement signals resolution of legal uncertainties for Apollomics, potentially stabilizing its stock and improving investor confidence in future operations and profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Apollomics Inc. (Nasdaq: APLM) announced updates to its board of directors and committee compositions on November 17, 2025.
Why It Matters
Board changes can signal strategic shifts or governance improvements, potentially affecting company performance and stock value, influencing investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About APLM Stock
What is Apolomics Inc.'s (APLM) stock forecast for 2027?
Analyst forecasts for Apolomics Inc. (APLM) are not currently available. The stock is trading at $14.21.
Is APLM stock a good investment in 2027?
Analyst ratings for APLM are not currently available. The stock is currently trading at $14.21. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APLM stock?
Price predictions from Wall Street analysts for APLM are not currently available. The stock is trading at $14.21.
What is Apolomics Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on the discovery and development of therapies that harness the immune system to combat cancer. It generates revenue through the advancement of its clinical assets, including late-stage candidates, which may lead to partnerships, licensing agreements, or eventual product sales upon successful commercialization.
What is the highest forecasted price for APLM Apolomics Inc.?
Price targets from Wall Street analysts for APLM are not currently available. The stock is trading at $14.21.
What is the lowest forecasted price for APLM Apolomics Inc.?
Price targets from Wall Street analysts for APLM are not currently available. The stock is trading at $14.21.
What is the overall APLM consensus from analysts for Apolomics Inc.?
Analyst ratings for APLM are not currently available. The stock is trading at $14.21.
How accurate are APLM stock price projections?
Stock price projections, including those for Apolomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 5:04 AM UTC